Translational research on gastric cancer: Ruijin experience
10.3760/cma.j.issn.1671-0274.2020.02.008
- VernacularTitle: 浅谈胃癌转化医学研究的"瑞金体会"
- Author:
Jianfang LI
1
;
Zhenggang ZHU
;
Bingya LIU
Author Information
1. Department of Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Institute of Digestive Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai 200025, China
- Publication Type:Journal Article
- Keywords:
Stomach neoplasms;
Translational medicine;
Biological markers;
Antibody;
Drug delivery
- From:
Chinese Journal of Gastrointestinal Surgery
2020;23(2):140-143
- CountryChina
- Language:Chinese
-
Abstract:
Translational medicine refers to translating basic research achievements into the clinical application for diagnosis and treatment. There are still many issues of gastric cancer to be solved in clinical diagnosis and treatment. We need to focus on clinical questions, by means of basic research and multidisciplinary intersection approach, to further improve the overall efficacy of gastric cancer. Based on Ruijin Hospital′s translational research experiences, in this paper, the authors describe the future direction in the field of translational research, such as the etiology and pathogenesis of gastric cancer, tumor markers for early diagnosis, prediction of recurrence and metastasis, classification criteria, evaluation of chemotherapy, tumor heterogeneity, targeted therapy, immunotherapy and research platform establishment. In addition, here we share our perspective of the research on serum biomarkers, specific antibodies and improvement of drug delivery for gastric cancer.
